Regarding the second question on the metabolism of Mestrano1,-the data cited on metabolism of Mestranol in animals comes from experimental studies, and I have no data on pharmacokinetics of Mestranol in man.
DR. MC KENZIE: There is one other point I would like to make. That is, in preparing your questionnaire, it's extremely important to be very specific in your questions. I had an experience in which a group of women were asked if they were taking oral contraceptives. They all said no. The question was posed another way-are you taking "the pill"? The answer was yes. So, one needs to be very careful in posing these questions. DR. BARROWS: I might add, both to the patient and her physician. To many physicians, the idea that a patient may be on contraception may be overlooked completely.
DR. R. F. MC CONNELL: Dr. Barrows, did I understand you correctly, that most of the proliferative nodules that you have seen in the human are associated with the estrogen component? DR. BARROWS: No. That's the only component that we studied in detail. Most received oral contraceptives, and the type of oral contraceptive (brand name) varies enormously. One of the reasons for studying the estrogenic component was because the speculation was raised that perhaps Ethynyl EsSradiol was more closely linked than Mestranol. We find that not to be the case. The problem in studying the progestational agents is the amounts of these and types of these vary enormously with different medication while the estrogenic components usually were fairly cons tan t.
DR. R. F. MC CONNELL Do you feel that the progesterone component is related to these particular lesions in the human? DR. BARROWS: We really have no data to indicate whether progesterone or estrogen components are more closely related.
DR. MC CONNELL: There is an interesting point for comment regarding Dr. Schuppler's data. It was of interest to note in Dr. Schuppler's rat studies, where a n injectable proges-, togen resulted in an increasing body burden of drug, that a dose dependent increase.of proliferative liver lesions resulted. Morphologically they would have fit today's criteria of neoplastic nodule. Since a high percentage of the animals were affected, wouldn't the progestogens have to be considered a fairly potent carcinogen in the rat? If that is the case, one would wonder that if we have such a low incidence of benign liver tumors associated with sex steroids in the human and such a high incidence of those lesions in the rat, whether or not, as Dr. Schuppler suggested, the rat is a very good model for predicting human cancer risk.
DR. SCHUPPLER: I didn't really get your question. As I said, I think the rat is an extremely sensitive model. As far as the question of the estrogen or gestagenic activity of sex steroids is concerned-in the rat we have a completely different situation than in man. If we say, for instance, in man Norethindrone, which is the active principle of norethindrone enanthate is a gestagen, then it is a gestagen, but it's not a gestagen for the rat. It's only about 70% gestagenic in the rat. It has two different effects. It has a gestagenic effect of about 70% and 30% estrogenic effect. I don't know if that answers your question.
DR. MC CONNELL The point that I was trying to make was that those of us who have experience in evaluating the tissue from rats dosed with progestagens at relatively high levels find that they commbnly have proliferative liver nodules. The lesions neither metastasize nor act aggressively. Under today's diagnostic criteria, we would have to at least call them neoplastic nodules. In your studies, Jorg, where you induced a high level of the lesions under the increasing body burden of drug, you will have to consider the compound a potent carcinogen under today's diagnostic criteria.
DR. SCHUPPLER: If you call something a potent carcinogen, then you also have to start talking about progesterone as a potent carcinogen because it causes mammary carcinoma in dogs. The hormonal situation is completely different to the classic carcinogens. I don't think one can compare them. From some of our promotional studies, we have the impression that progesterone does exactly the same thing. We have exactly the same thing with the natural sex hormone progesterone as we do with Cyproterone Acetate. It has the same effect. As somebody has said, the best way, I think, to protect against breast cancer is to castrate all women. It's too easy to just stand up and say-hormones are carcinogenic. Let's just assume that they act epigenetically, then we must also presumably accept a threshold value and a threshold dose below which they do not act.
DR. BANNASCH: Could you perhaps add a few remarks on the cell types composing the adenomas that you see in humans? Do you feel that they are comparable to the nodules found in the rat? The second question would be-do you ever see, in addition to these nodular lesions, focal lesions which might also be comparable to those in the rat? DR. BARROWS: To answer the second question first-the problem with focal nodules; in the adjacent liver to these we do not see so-called preneoplastic foci. Of course, in these women, the remainder of the liver is not examined, so we have n o opportunity to study that. In those cases from autopsy, we have not seen so-called preneoplastic changes in adjacent liver, but our sample is small. Regarding the type of nodule there's a wide variety in the adenomas. There are some'that have a high glycogen content with a clear cell appearance. There is no consistent finding that you could apply directly to relate the rat nodules and human liver tumors. Even between rats and mice, the histology of the lesions varies considerably, so I'm not really sure you would expect it to be the same in species as different as man and rat.
